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Background: Ipilimumab, a human monoclonal antibody that blocks cytotoxic T-Lymphocyte antigen CTLA-4 has 
demonstrated activity in patients with advanced (unresectable or metastatic) malignant melanoma. Up to 60% of patients 
treated with Ipilimumab develop immune-related adverse effects, usually occurring in the first twelve weeks. However, 
we present a case of hypopituitarism presenting over two months following final treatment with Ipilimumab, without 
radiological or clinical evidence of pituitary enlargement. 
Case presentation: A 70 year old woman with a history of metastatic melanoma presented two months following 
complete response to treatment with Ipilimumab. She complained of increasing fatigue, extreme weakness, somnolence 
and confusion. Initial laboratory results revealed hyponatraemia and hypothyroidism.  
Conclusions: While immune-related adverse effects are found in the majority of patients treated with Ipilimumab and 
cases of hypopituitarism are well documented, these are usually not acute and tend to progress sub-clinically. The onset 
of hypopituitarism observed in this patient, bearing in mind the lack of clinical and radiological evidence of pituitary 
enlargement, suggests that the auto-immune response induced by the anti-CTLA- 4 may additionally lead to clinical 
presentation even after a period from treatment cessation, without any clinically evident acute phase of inflammation. 
This may reflect the development of pituitary directed antibodies. Thus, we present a case of a previously unseen 
presentation of hypopituitarism secondary to Ipilimumab which will aid in its’ diagnosis and management. 
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Background 
Ipilimumab, a human monoclonal antibody that blocks cytotoxic T-Lymphocyte antigen CTLA-4 has 
demonstrated activity in patients with advanced (unresectable or metastatic) malignant melanoma. Up to 
60% of patients treated with Ipilimumab develop immune-related adverse effects, usually occurring in the 
first twelve weeks. However, we present a case of hypopituitarism presenting over two months following 
final treatment with Ipilimumab, without radiological or clinical evidence of pituitary enlargement. 
Case Report 
A 70-year-old Caucasian female with a history of a resected lentigo maligna melanoma 5 years earlier 
was admitted with cerebellar features. A Cerebellar vermis metastasis had been confirmed radiologically 
(Fig 1). Her baseline staging computed tomography (CT) revealed left pulmonary nodules and tiny 



















Fig1A: Contrast-enhanced CT brain reveal a 1.7 cm multiple hypodense lesion with surrounding oedema within the 
cerebellar vermis.  
Fig1B: Axial T1-weighted MRI showing an enhancing lesion in the cerebellar vermis and also a lesion in the left 
parietal region.  
 
She had been treated with Whole Brain Radiotherapy (WBRT) for presumed metastatic melanoma. 
Furthermore, post WBRT a Positron-Emission Tomography- Computed Tomography (PET-CT) showed 
multiple suspicious lesions in both lungs as well as in spleen. In the liver solitary fluoro-2-deoxyglucose 
positron (FDG) avid lesion highly suspicious of metastatic focus was visible (Fig 2). 
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Fig 2 A: Coronal PET image shows the hypermetabolic splenic metastasis. 
Fig 2 B: Lung metastases are demonstrated on axial PET. 
 
Histopathological examination of an ultrasound-guided biopsy confirmed liver metastasis from a 

















Fig 3: Histological examination indicates Large cells with pleomorphic vesicular nuclei, prominent nucleoli and 
large eosinophilic cytoplasm (hematoxylin and eosin, 400X) 
Ivy Union Publishing | http: //www.ivyunion.org August 3, 2016 | Volume 4, Issue 2 
Ahmed YA et al. American Journal of Cancer Case Reports 2015, 4:106-113
6
Page 4 of 8 
 
The patient was treatment naïve, in very good performance status (Eastern Cooperative Oncology 
Group Performance Status of 1) and with normal organs function. She was considered for cytotoxic 
T-lymphocyte antigen 4 (CTLA4) blockade to treat the unresectable Stage IV melanoma. Four cycles of 
Ipilimumab 3 mg/kg were given without any substantial side effects and she achieved a complete clinical 
and radiological response. 
Two months after the final treatment, the patient presented with complaints of increasing fatigue, extreme 
weakness, somnolence and confusion. She denied nausea, vomiting, visual symptoms, polydipsia or 
polyuria. She did not have other co-morbidities or family history of endocrine problems or malignancy. 
Initial laboratory evaluation revealed low sodium of 125[133-145] mmol/L and inappropriately low 
free T4 < 5.2 [9-19] pmol/L with normal TSH 0.52 [0.35-4.94] uIU/ml. Previous thyroid function studies 
obtained before Ipilimumab were normal. 
CT of the head (Fig 4 A).followed by contrast-enhanced magnetic resonance imaging (MRI) showed 


















Fig 4A: Contrast-enhanced CT brain revealed a complete resolution of the previously noted vermis lesion.  
Fig 4B: MRI brain showing normal brain enhancement and normal appearance of pituitary gland. 
 
A more complete assessment of pituitary function was undertaken by Endocrinology team, and the 
biochemical findings confirmed central hypocortisolism (random cortisol 16 nmol/L [reference range 
180-620] and hypothyroidism, FSH 4.8 mIU/ml, LH 0.4 mIU/ml. Oestradiol Serum <92 pmol/L. 
There was no diabetes insipidus; her prolactin was 10.2 [5.18-26.53] ng/ml and the serum IGF-1 was 
normal [13.5nmol/L, normal range 10.5-35 nmol/L].  
A glucagon stimulation test was carried out initially. [Table 1] This proved an adult growth hormone 
deficiency was present. 
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 0 mins 60 mins 120 mins 180mins 
Cortisol 18 20 19 21 
Growth Hormone <0.3 0.4 0.4 <0.3 
 
A Synacthen Test was then carried out [Table 2] which was positive for adrenal insufficiency. 
 0 mins 30 mins 
Cortisol 18 173 
She was diagnosed with hypopituitarism, secondary to Ipilimumab treatment. She was commenced 
on dexamethasone 0.75 mg twice daily and three days later Levothyroxine 100mcg daily was added. 
These resulted in rapid resolution of the hyponatremia and gradual improvement of her cognitive function. 
Follow-up eight and sixteen weeks later showed full resolution of symptoms, with the patient to remain 
on maintenance dose of steroids and levothyroxine. 
Discussion  
Advanced melanoma is characterized by disseminated metastatic disease which carries very poor 
prognosis with a median survival of 8–9 months .In those patients the estimated 3-year survival rate of 
less than 15 %[1]. It has high propensity of metastasize to the central nervous system and is the third most 
common solid tumor causing cerebral metastases, after lung and breast cancers [2]. 
Melanoma brain metastases (MBM) is the most devastating event in the course of melanoma carries 
that is responsible for 20 -54 % of deaths in patients with melanoma[1] .The prevalence of MBM is about 
20–40% in clinical series and up to 75% in autopsy series[2]. The conventional management of MBM 
remains challenging due to the limited treatment options.It consists of surgical resection, whole brain 
radiotherapy and stereotactic radiotherapy to achieve local disease control[2, 3].  
Prior to 2011, dacarbazine (DTIC) and interleukin-2 (IL-2) immunotherapy were the only two 
systemic therapeutic agents available, however, traditionally melanoma has been resistant to treatment 
with conventional chemotherapy. 
Most recently Clinical results from the development of immunotherapy agents such as Ipilimumab 
and targeted therapies such as dabrafenib and vemurafenib suggest that systemic therapy may have a role 
in carefully selected patients with MBM [4]. 
Ipilimumab, a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen CTLA-4 
helps regulate the balance between immune activation and tolerance, has demonstrated activity in patients 
with advanced melanoma. Clinical trial data suggest that Ipilimumab has activity in patients with brain 
metastases [4]. 
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Since its approval in 2011 by the Food and Drug Administration and the European Medicines 
Agency, Ipilimumab, has become a standard treatment option for patients with advanced (unresectable or 
metastatic) malignant melanoma. 
In randomized, controlled phase 3 trials, Ipilimumab significantly improved overall survival (OS) in 
both pretreated and treatment- naı¨ve patients with metastatic melanoma[5,6]. Also, intracranial antitumor 
activity of Ipilimumab has been demonstrated in a multicenter Phase II study [6]. 
Immune-stimulatory therapy, predictably generates autoimmunity causing immune-related adverse events 
(IRAE) in the majority of patients. In the phase III trial that demonstrated an increase in survival, IRAE 
occurred in approximately 60 % of patients treated with Ipilimumab [5]. The most common serious 
manifestations include enterocolitis, hepatitis, dermatitis, and endocrinopathy. IRAE occur during the first 
12 weeks and the median time to resolution is approximately 6 weeks for grade 2 IRAE and 8 weeks for 
grade 3 and 4 IRAE [7]. 
The incidence of IRAE endocrinopathy in Ipilimumab phase II and III trials of 1498 patients was 
<5%, with <3% being grade 3 or higher [8]. The most common endocrinopathy was hypophysitis with 
hypopituitarism in 0–17%, followed by hypo- and hyperthyroidism secondary to thyroiditis in 2.7 and 
0.3% respectively, and adrenal insufficiency in 2.1% [8] .Usually, the clinical onset of these endocrine 
IRAE is not acute and they progress subclinically [9].  
Hypopituitarism is thought to be an infrequent disease, with an incidence of 4.2 cases per 100,000 
per year & Hypophysitis is among the rarest causes of hypopituitarism [10]. Autoimmune hypophysitis 
(AH), often referred to as lymphocytic hypophysitis is characterized by dense diffuse lymphocytic 
infiltration of the pituitary and usually is confined to the anterior pituitary [9]. 
Patients who experience anti–CTLA-4 Autoimmune hypophysitis usually present with nonspecific 
symptoms such as headache, visual impairment, fatigue, weakness, confusion, memory loss, erectile 
dysfunction and loss of libido, anorexia, labile moods, insomnia, temperature intolerance, subjective 
sensation of fever, and chills [9]. Most patients developed relevant symptoms after a median time of 9.4 
weeks ( range 6-12 weeks ) suggesting a possible cumulative effect [5]. 
In contrast to other forms of AH Levels of ACTH, cortisol, TSH and/or free T4, GH, prolactin, 
IGF-1, FSH, LH, and testosterone are variably altered, indicating different degrees of hypopituitarism 
[9,10]. A rare presentation of hyponatremia due to the syndrome of inappropriate anti-diuretic hormone 
(SIADH) secretion was reported in a single case [11]. There is also a single case report describing 
diabetes insipidus [12]. 
It is unclear why the anterior pituitary is particularly susceptible to Ipilimumab therapy .In the 
published literature, the posterior pituitary function remained normal in most of the cases, suggesting a 
possible predilection of Ipilimumab for corticotrophic and probably thyrotrophic cells [6,9,12–15]. 
In contrast to most cases of lymphocytic hypophysitis which are accompanied by uniform pituitary 
enlargement [9,16,17], MRI in this case showed a normal sized pituitary gland without evidence of 
pathological post contrast enhancement. This is in keeping with what is previously reported in about 20 % 
of patients with hypophysitis following Ipilimumab[9,17]. The typical MRI hypophysitis enlargement 
usually resolve in 4-6 weeks [17], however, it has been reported to resolve after 3 months [18]. 
The onset of anterior lobe hypopituitarism we observed in this patient and given the lack of clinical 
and radiological evidence of pituitary enlargement suggests that the auto-immune response induced by the 
anti–CTLA-4 may additionally lead to clinical presentation even after a period from the treatment 
cessation, without a clinically evident acute phase of inflammation. This could reflect the development of 
pituitary-directed antibodies.It is generally accepted that the hypophysitis is not reversible. Long-term or 
even lifelong hormone therapy will be frequently required [9,12,18]. 
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Several issues concerning anti–CTLA-4 –autoimmune hypophysitis are still unknown .The exact 
incidence of this and other EIRAEs and the role of CTLA-4 gene polymorphisms, which are known to 
correlate with certain autoimmune endocrinopathies such as Graves disease and Hashimoto thyroiditis, 
need to be better clarified in larger studies. 
Also the correlation between tumor response and the incidence and severity of IRAEs needs to be 
defined using an appropriate analytical approach. The development of IRAEs appears to be associated 
with antitumor response and longer survival in some studies. Having said that disease survival and 
benefits with Ipilimumab were similar among patients with or without IRAE. 
It is still unclear whether the effects result from T cells specifically acting against antigens shared by 
tumour and normal cells or from the concomitant activation of multiple T cells populations with separate 
anti-host and tumour activity  
While immune-related adverse effects are found in the majority of patients treated with Ipilimumab 
and cases of hypopituitarism are well documented, these are usually not acute and tend to progress 
subclinically. The onset of hypopituitarism observed in this patient, bearing in mind the lack of clinical 
and radiological evidence of pituitary enlargement, suggests that the auto-immune response induced by 
the anti-CTLA- 4 may additionally lead to clinical presentation even after a period from treatment 
cessation, without any clinically evident acute phase of inflammation. This may reflect the development 
of pituitary directed antibodies. Thus, we present a case of a previously unseen presentation of 
hypopituitarism secondary to Ipilimumab which will aid in its’ diagnosis and management. 
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